APA

Vaughan A. T., Iriyama C., Beers S. A., Chan C. H. T., Lim S. H., Williams E. L., Shah V., Roghanian A., Frendéus B., Glennie M. J. & Cragg M. S. (20140326). Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. : Blood.

Chicago

Vaughan Andrew T, Iriyama Chisako, Beers Stephen A, Chan Claude H T, Lim Sean H, Williams Emily L, Shah Vallari, Roghanian Ali, Frendéus Bjorn, Glennie Martin J and Cragg Mark S. 20140326. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. : Blood.

Harvard

Vaughan A. T., Iriyama C., Beers S. A., Chan C. H. T., Lim S. H., Williams E. L., Shah V., Roghanian A., Frendéus B., Glennie M. J. and Cragg M. S. (20140326). Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. : Blood.

MLA

Vaughan Andrew T, Iriyama Chisako, Beers Stephen A, Chan Claude H T, Lim Sean H, Williams Emily L, Shah Vallari, Roghanian Ali, Frendéus Bjorn, Glennie Martin J and Cragg Mark S. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. : Blood. 20140326.